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Abstract
The duration of antimicrobial therapy after surgery for infective endocarditis (IE) is controversial. A short course of postsurgical therapy
is currently accepted only for patients with negative valve culture. We performed a retrospective (1994–2008) analysis of patients who
underwent surgery for IE in our hospital and had a high risk of complications ( one of more of the following: <2 weeks of antibiotic
treatment before surgery; embolism; perivalvular extension; and positive valve culture) to compare outcomes of patients who received
short-course antimicrobial therapy (SAT) (median 15 days) or long-course antimicrobial therapy (LAT) (median 32 days), irrespective of
the results of valve culture. Our endpoints included length of hospital stay, renal and hepatic failure, relapse, re-infection, and mortality
rates 1 year after surgery. During the study period, 140 patients underwent surgery for IE (valve replacement, 87.9%). Of these, 133 ful-
ﬁlled the high-risk group criteria and 92 completed the antimicrobial schedule. Comparison of patients receiving SAT (37) and LAT (55)
showed that the SAT group had a shorter length of hospital stay (29 vs. 40 days, p 0.01), and a trend towards lower frequency of renal
failure (5.4% vs. 18.2%, p 0.11) and hepatic failure (5.4% vs. 9.1%, p 0.69), whereas mortality (5.4% vs. 3.6%, p 1), relapse (0% vs. 1.8%,
p 1) and re-infection (5.4% vs. 3.6%, p 1) rates were similar between both groups. Multivariate analysis showed that IE caused by Strep-
tococcus viridans or Streptococcus bovis was independently associated with SAT. Postsurgical SAT is safe, especially when IE is caused by
Streptococcus viridans or Streptococcus bovis, even in patients at high risk of complications.
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Introduction
The incidence of infective endocarditis (IE) ranges between
three and 10 cases/100 000 inhabitants/year, varying by coun-
try and type of patient [1–3]. Prolonged antimicrobial ther-
apy is considered to be an essential part of the treatment of
IE, although surgery is increasingly used and is currently per-
formed in 30–50% of cases [4–6].
In patients undergoing heart surgery for IE, the optimal
length of antibiotic therapy after surgical excision is an
unresolved issue. Current European guidelines recommend
administering the complete course of treatment if the
resected tissue is culture-positive, and completion of the
prescheduled course if it is culture-negative [7]. Morris
et al. [8] suggested that a 2-week postsurgical course of
treatment was not associated with higher relapse rates if
the result of valve culture was negative, even in patients
with perivalvular invasion. In any case, relapse caused
by the same microorganism after surgery is very uncom-
mon [8], and the length of treatment after surgical resec-
tion of valvular tissue in IE is not based on robust clinical
studies.
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We selected a sample of patients with IE at high risk of
complications who were referred for surgical resection, in
order to compare the outcomes of those receiving
short-course antimicrobial therapy (SAT) or long-course
antimicrobial therapy (LAT) postoperatively, irrespective of
the culture results of valvular tissue.
Materials and Methods
Setting
Our hospital is a 1750-bed tertiary-referral general teaching
institution, serving a population of approximately 715 000
inhabitants. It has a very active major heart surgery pro-
gramme that includes heart transplantation and referrals of
patients with IE.
Study design
Episodes of IE were identiﬁed prospectively. Demographic,
clinical, diagnostic, therapeutic and outcome data were col-
lected in a pre-established protocol and entered into a data-
base. On average, we diagnose 47 episodes of IE per year.
Patients were retrospectively selected for this study if they
underwent surgery for IE from 1 January 1994 to 31 Decem-
ber 2008.
Our objective was to compare outcomes in patients at
high risk of complications who received SAT and LAT
according to the prescription of the attending physician.
We considered patients to be at high risk if they pre-
sented one or more of the following conditions: <2 weeks
of antibiotic treatment before surgery; embolism; perivalvular
extension, including abscesses, pseudoaneurysm, and perfora-
tion and dehiscence of a prosthetic valve; and positive cul-
ture of valve tissue.
The SAT group comprised those patients who received a
maximum of 20 days of antimicrobial therapy after surgery.
The LAT group comprised those patients who received a
minimum of 21 days of treatment after surgery.
Treatment management
Empirical antibiotic therapy was started in all patients with
suspicion of IE in accordance with ofﬁcial recommendations
[7,9].
Antimicrobial regimen, surgical management and duration
of treatment were established by the attending physicians,
following the advice of the GAME multidisciplinary group.
Brieﬂy, our therapeutic protocol was as follows. For
native valve IE caused by methicillin-susceptible Staphylococcus
aureus (MSSA), we used cloxacillin (2 g every 4 h) with or
without a short course (5–7 days) of gentamicin (1 mg/kg
every 8 h); for prosthetic valve IE caused by MSSA, we used
combined therapy with cloxacillin and rifampicin (300 mg
every 8 h) plus gentamicin for the ﬁrst 2 weeks; for native
valve IE caused by methicillin-resistant S. aureus, we used
vancomycin (1 g every 12 h) with or without a short course
of gentamicin; for prosthetic valve IE caused by methicillin-
resistant S. aureus, we used combined therapy with vanco-
mycin and rifampicin, plus gentamicin for the ﬁrst 2 weeks;
for IE caused by viridans group streptococci, we used ceftri-
axone (2 g every 24 h) with or without gentamicin; and for
IE caused by Enterococcus faecalis, we used ampicillin (2 g
every 4 h) plus gentamicin or high doses of ceftriaxone (2 g
every 12 h). Combined oral therapy with ciproﬂoxacin plus
rifampicin was used in intravenous drug users with right-
sided IE caused by MSSA, according to susceptibility testing.
For other aetiologies, we invited attending physicians to con-
sult the game. The duration of treatment was individualized
according to the site, aetiology and complications of IE, the
result of valve culture, and the tolerance of patient to the
treatment.
Surgical protocol
A cardiac surgeon evaluated all patients with a diagnosis of
IE. Early surgery was the approach taken—when feasible—in
patients with cardiac failure, multiple emboli, perivalvular
extension, or uncontrolled infection despite appropriate anti-
biotic therapy.
Prophylaxis was administered 30–60 min prior to incision,
and consisted of cefazolin or vancomycin for patients who
were allergic to penicillin. For procedures lasting more than
4 h in patients receiving cefazolin, a second intraoperative
dose was administered.
During surgery, every attempt was made to remove all
infected tissue and foreign material.
Microbiological protocol
At least three sets of aerobic and anaerobic blood cultures
were performed for patients with fever or suspected IE.
Blood was cultured with the BACTEC 9240 system (Becton-
Dickinson, Sparks, MD, USA), and bottles were incubated at
37C for a maximum of 20 days. Positive samples were char-
acterized by Gram stain, and subcultured on Columbia sheep
blood agar, chocolate agar supplemented with Isovitalex, and
Brucella agar, before incubation for 5 days at 37C in air, 5%
CO2, and an anaerobic atmosphere, respectively. Identiﬁca-
tion of and susceptibility testing for the bacteria isolated
were performed with MicroScan panels (Siemens Healthcare
Diagnostic, West Sacramento CA, USA) and conventional
microbiological procedures [10,11], according to CLSI rec-
ommendations [12].
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We systematically cultured all heart valves and, from 1
January 2005, molecular investigation was also performed.
Valves were transported to the microbiology laboratory at
the end of the operation in a sterile container. Culture and
molecular techniques were as described elsewhere [13,14].
Valve cultures were classiﬁed as true/false-positive/negative
according to the results of blood culture, serology, universal
PCR of the 16S rRNA gene (PCR 16S rRNA) and sequencing
as previously described [13]. We considered the valve cul-
ture to be a true-positive when the result matched that of
blood cultures, or that of PCR 16S rRNA in cases of IE with
negative blood cultures.
In the case of repeated IE caused by the same species, we
performed pulsed-ﬁeld gel electrophoresis in accordance
with standard procedures [15] to conﬁrm that the two iso-
lates had the same ﬁngerprint.
Follow-up
After discharge, patients were followed at our clinic for up
to 1 year. We performed echocardiography at the end of
treatment in all patients and also at follow-up visits. We per-
formed a review of all patients’ records in order to detect
repeated IE or mortality.
Deﬁnitions
The modiﬁed Duke criteria were used to deﬁne IE [16]. We
considered the IE episode as community-acquired or health
care-associated on the basis of the classiﬁcation of the Inter-
national Collaboration on Endocarditis study group [6].
Regarding predisposing conditions, previous valve disease
included rheumatic valve disease, valve hypertrophic stenosis,
and mitral prolapse. Endocavitary devices included pacemak-
ers and implantable cardioverter deﬁbrillators.
With subsequent episodes of IE, we differentiated relapse
from re-infection. Relapse was deﬁned as a repeated episode
of IE caused by the same microorganism <6 months after
the initial episode [7]. Re-infection was deﬁned as a repeated
episode of IE caused by a different microorganism, or by the
same microorganism but >6 months after the initial episode
[7].
Postsurgical renal failure was deﬁned as a drop in creati-
nine clearance of 25% or as an increase in creatinine levels
above 1.4 mg/dL in patients with previously normal values.
Postsurgical hepatic failure was deﬁned as new hepatic insuf-
ﬁciency or worsening of the Child–Pugh classiﬁcation in
patients with a history of hepatic disease.
Statistical analysis
In the univariate analysis, categorical variables were com-
pared by use of the chi-square test. Non-normally distributed
continuous variables were compared by use of the Mann–
Whitney U-test, and expressed as the median and interquar-
tile range. The normally distributed continuous variables
were compared by use of the t-test, and expressed as the
mean and standard deviation. To determine the power of
our study to detect signiﬁcant differences in mortality,
relapse and re-infection between the SAT and LAT groups,
we used the standard formula [17]. Stepwise logistic regres-
sion models were used in the multivariate analysis to analyse
factors independently associated with SAT. Variables with a
p-value £0.1 in the univariate analysis were included in the
multivariate models. Differences were considered to be sig-
niﬁcant for p-values <0.05. The analysis was carried out with
SPSS 18.0 (SPSS, Chicago, IL, USA).
Results
During the study period, 140 patients underwent surgery for
IE. Of these, 123 (87.9%) had a valve replacement and the
remaining 17 underwent different procedures (Table 1).
The main causative agents were S. aureus (20.7%), coagu-
lase-negative staphylococci (17.9%), and Streptococcus viridans
(17.9%) (Table 2). In three of the 12 cases of IE with nega-
tive blood cultures, we were able to assess the aetiology by
combined serology and PCR 16S rRNA (Coxiella burnetii,
Bartonella quintana, and Tropheryma whipplei).
Overall, 133 patients fulﬁlled the high-risk group criteria
(<2 weeks of treatment before surgery, 107; perivalvular
invasion, 75; one or more embolic events, 58; and positive
valve culture, 37). We analysed the 92 patients who survived
to complete the programmed antimicrobial schedule.
The remaining 41 patients died in the hospital during the
antimicrobial treatment at a median of 10 days (interquartile
range 1–21) after surgery.
The comparison of patients who received SAT (37) and
LAT (55) is shown in Table 3. The median duration of post-
surgical antimicrobial therapy was 15 days in the SAT group
and 32 days in the LAT group. In the SAT group, seven
patients were treated for between 16 and 19 days; in the
LAT group, 18 of 55 patients were treated for between 21
and 28 days. Of these, ten patients received 21 or 22 days
of postsurgical antimicrobial therapy, and none suffered
relapse or re-infection; one patient died 2 months after hos-
pital discharge from another cause (gastrointestinal bleeding).
SAT patients more frequently had congenital heart disease
(13.5% vs. 0%, p 0.009), left-sided native valve IE (78.4% vs.
56.4%, p 0.04), valve perforation (29.7% vs. 10.9%, p 0.03),
and Streptococcus viridans as the aetiological agent (43.2% vs.
5.5%, p <0.001). The frequencies of endocavitary device use
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(2.7% vs. 21.8%, p 0.01) and positive valve culture (13.5% vs.
38.8%, p 0.01) were lower in SAT patients. Multivariate anal-
ysis adjusted for age, Charlson comorbidity index, prosthetic
material and bacterial species showed that Streptococcus viri-
dans and Streptococcus bovis as aetiological agents of IE were
independently associated with SAT, whereas a positive result
of valve culture was independently associated with LAT
(Table 4).
With respect to outcome, SAT patients had a shorter
length of hospital stay (29 vs. 40 days, p 0.01), whereas the
mortality (5.4% vs. 3.6%, p 1), relapse (0% vs. 1.8%, p 1) and
re-infection (5.4% vs. 3.6%, p 1) rates were similar in both
groups, with a statistical power of approximately 60%. With
respect to renal and hepatic failure after surgery, we
observed a lower incidence in patients receiving SAT (5.4%
vs. 18.2% and 5.4% vs. 9.1%, respectively), although the dif-
ference was not statistically signiﬁcant.
Overall, 24 patients had a positive culture at surgery: 19
were receiving LAT and ﬁve SAT, and there were no differ-
ences in outcome between them (Table 5). The characteris-
tics of the ﬁve SAT patients with a positive valve culture are
shown in Table 6.
No episodes of relapse and two episodes of re-infection
were observed in the SAT group. One occurred in an active
intravenous drug user 1 year after the end of treatment, and
was caused by MSSA, as in the previous IE episode, but with
a different ﬁngerprint detected in the pulsed-ﬁeld gel electro-
phoresis analysis. The other was observed in a patient with
prostatic hypertrophy and mitral IE caused by Aerococcus
urinae (positive blood culture and negative valve culture). He
underwent valve replacement and completed 2 weeks of cef-
triaxone treatment after surgery, although the urinary tract
obstruction did not resolve. Ten months later, the patient
presented with dehiscence of the prosthetic valve, along with
positive blood cultures for Streptococcus agalactiae and signs
of obstructive renal failure. A second valve replacement and
transurethral prostatic resection were performed. The
patient was cured with a full 4-week course of ceftriaxone,
and no further IE episodes occurred during the 1-year
follow-up.
In the LAT group, we observed a relapse of prosthetic
aortic valve IE caused by the same microorganism (Staphylo-
coccus epidermidis) 3 months after the end of the 4-week
postsurgical treatment. Unfortunately, isolates were not
TABLE 1. Baseline characteristics of 140 patients who
underwent surgery for infective endocarditis
Variable N = 140
Age (years)
Mean ± SD 59.1 ± 15.6
Sex, no. (%)
Male 90 (64.3)
Female 50 (35.7)
Underlying conditions
None, no. (%) 23 (16.4)
Diabetes mellitus, no. (%) 25 (17.9)
Cancer, no. (%) 15 (10.7)
HIV infection, no. (%) 8 (5.7)
Haemodialysis, no. (%) 7 (5)
Charlson comorbidity index (median (IQR)) 3 (2–5)
Predisposing conditions, no. (%)
Previous valve disease 81 (57.9)
Endocavitary device 17 (12)
Current IV drug use 10 (7.1)
Congenital heart disease 9 (6.4)
Previous IE 9 (6.4)
IE type, no. (%)
Left-sided NVE 88 (62.9)
Left-sided PVE 46 (32.9)
Early, <1 year 22/46 (48)
Right-sided IE 6 (4.3)
Community-acquired 106 (75.7)
Healthcare-associated 34 (24.3)
Nosocomial 28/34 (82.3)
Aortic valve 82 (58.6)
Mitral valve 75 (53.6)
Both 29 (20.7)
Type of surgery, no. (%)
Valve replacement 123 (87.9)
Homograft insertion 9 (6.4)
Mitral annuloplasty 4 (2.9)
Valve repair 3 (2.1)
Tricuspid annuloplasty 1 (0.7)
Length of hospital stay (median (IQR))
Total days of hospital stay 34.5 (22–51)
Days of hospital stay after surgery 17 (10–30.7)
Mortality, no. (%)
£2 days after surgery 13 (9.3)
3–15 days after surgery 12 (8.6)
16–197 days after surgery 21 (15)
Repeated IE, no. (%)
Relapse 1 (0.7)
Re-infection 4 (2.9)
HIV, human immunodeﬁciency virus; IE, infective endocarditis; IQR, interquartile
range; IV, intravenous; NVE, native valve endocarditis; PVE, prosthetic valve
endocarditis; SD, standard deviation.
TABLE 2. Aetiology of the 140 episodes of infective endo-
carditis
Causative agent N (%)
Staphylococcus species
S. aureus 29 (20.7)
MSSA 23/29 (79.3)
MRSA 6/29 (20.7)
Coagulase-negative staphylococci 25 (17.9)
Streptococcus species
Streptococcus viridans 25 (17.9)
Streptococcus bovis 8 (5.7)
Streptococcus agalactiae 6 (4.3)
Streptococcus pneumoniae 2 (1.4)
Streptococcus pyogenes 1 (0.7)
Other 5 (3.5)
Enterococcus faecalis 12 (8.6)
Other Gram-positive 6 (4.3)
HACEK group 2 (1.4)
Other Gram-negative 2 (1.4)
Fungi
Candida species 4 (2.9)
Aspergillus fumigatus 1 (0.7)
Negative blood culture
Not determined 9 (6.4)
Bartonella quintana 1 (0.7)
Coxiella burnetii 1 (0.7)
Tropheryma whippelii 1 (0.7)
Total 140
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus.
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available, thus preventing molecular analysis of strain related-
ness. The two episodes of re-infection in this group
occurred within 6 months of the end of treatment, but with
different microorganisms (Streptococcus viridans and Enterococ-
cus gallinarum in one case, and S. epidermidis and Streptococcus
bovis in the other).
In the SAT group, 30 patients (81%) received less than
2 weeks of antimicrobial therapy before surgery. The two
cases of re-infection (caused by another pathogen) described
in the SAT group occurred among these patients. Both of
them had clear predisposing factors (intravenous drug use
and urinary tract obstruction).
TABLE 3. Comparison of high-risk patients with infective
endocarditis receiving short-course antimicrobial therapy
(SAT) or long-course antimicrobial therapy (LAT) after surgery
SAT group
N = 37
LAT group
N = 55
p
Demographic data
Age (years) (mean ± SD) 56.8 ± 17.9 57.8 ± 16.2 0.76
Male, no. (%) 21 (56.8) 41 (74.5) 0.11
Female, no. (%) 16 (43.2) 14 (25.5)
Underlying conditions
None, no. (%) 9 (24.3) 6 (10.9) 0.15
Diabetes mellitus, no. (%) 6 (16.7) 7 (12.7) 0.76
Cancer, no. (%) 0 6 (10.9) 0.08
HIV infection, no. (%) 3 (8.1) 3 (5.5) 0.68
Haemodialysis, no. (%) 0 5 (9.1) 0.08
Charlson comorbidity
index (median (IQR))
3 (1–4) 3 (2–5) 0.09
Predisposing conditions, no. (%)
Previous valve disease 18 (48.6) 30 (54.5) 0.67
Endocavitary device 1 (2.7) 12 (21.8) 0.01
Current IV drug use 1 (2.7) 6 (10.9) 0.23
Congenital heart disease 5 (13.5) 0 0.009
Previous IE 2 (5.4) 4 (7.3) 1
IE types, no. (%)
Left-sided NVE 29 (78.4) 31 (56.4) 0.04
Left-sided PVE 8 (21.6) 19 (34.5) 0.24
Early, <1 year 3 (37.5) 6 (31.6) 1
Right-sided IE 0 5 (9.1) 0.08
Community-acquired 35 (94.6) 44 (80) 0.06
Healthcare-associated 2 (5.4) 11 (20) 0.06
Nosocomial 2 (5.4) 8 (14.5) 0.31
Aortic valve 19 (51.4) 35 (63.6) 0.28
Mitral valve 21 (56.8) 23 (41.8) 0.2
Both 4 (10.8) 12 (21.8) 0.26
High-risk variables, no. (%)
Positive valve culture 5 (13.5) 19 (38.8) 0.01
£2 weeks of ABT
before surgery
30 (81.1) 45 (81.8) 1
Embolic events 14 (37.8) 25 (45.5) 0.83
CNS 8 (21.6) 15 (27.3) 0.63
Skin 6 (16.2) 13 (23.6) 0.44
Liver 1 (2.7) 5 (9.1) 0.39
Bone 3 (8.1) 5 (9.1) 1
Ocular 0 4 (7.3) 0.14
Perivalvular extension 20 (54.1) 28 (50.9) 0.83
Abscess 11 (29.7) 20 (36.4) 0.65
Valve perforation 11 (29.7) 6 (10.9) 0.03
Pseudoaneurysm 2 (5.4) 0 0.16
Dehiscence of prosthetic
valve
4 (10.8) 9 (16.4) 0.55
Aetiology, no. (%)
Staphylococcus aureus 3 (8.1) 12 (21.8) 0.09
MRSA 0 3 (5.5) 0.27
Coagulase-negative
staphylococci
4 (10.8) 13 (23.6) 0.17
Streptococcus viridans 16 (43.2) 3 (5.5) <0.001
Streptococcus bovis 5 (13.5) 2 (3.6) 0.11
Enterococcus faecalis 3 (8.1) 5 (9.1) 1
Candida spp. 0 2 (3.6) 0.51
Antibiotic treatment
Days of ABT after surgery
(median (IQR))
15 (14–15) 32 (24–42) <0.001
Use of aminoglycoside, no. (%) 28 (75.7) 34 (61.8) 0.18
Outcome
Renal failure, no. (%) 2 (5.4) 10 (18.2) 0.11
Hepatic failure, no. (%) 2 (5.4) 5 (9.1) 0.69
Total days of hospital stay
(median (IQR))
29 (22–43) 40 (31–58) 0.01
Days of stay after surgery
(median (IQR))
15 (11–18) 27 (17–40) <0.001
Mortality after
discharge, no. (%)
2 (5.4) 2 (3.6) 1
Relapse, no. (%) 0 1 (1.8) 1
Re-infection, no. (%) 2 (5.4) 2 (3.6) 1
ABT, antibiotic therapy; CNS, central nervous system; HIV, human immunodeﬁ-
ciency virus; IE, infective endocarditis; IQR, interquartile range; IV, intravenous;
MRSA, methicillin-resistant S. aureus; NVE, native valve endocarditis; PVE, pros-
thetic valve endocarditis; SD, standard deviation.
The bold values indicate the differences statistically signiﬁcant.
TABLE 4. Multivariate analysis for factors independently
associated with short-course antimicrobial therapy, adjusted
for age, Charlson comorbidity index, presence of prosthetic
material, and the bacterial species causing infective endo-
carditis (IE)
Adjusted OR (95% CI) p
IE caused by Streptococcus viridans 16.06 (3.80–67.92) <0.001
IE caused by Streptococcus bovis 6.21 (1.02–37.62) 0.047
Positive result of valve culture 0.22 (0.06–0.83) 0.025
TABLE 5. Comparison of patients with positive valve cul-
tures who received short-course antimicrobial therapy
(SAT) and long-course antimicrobial therapy (LAT) after
surgery
SAT group,
N = 5
LAT group,
N = 19 p
Demographic data
Age (years)
(mean ± SD)
36 ± 14.3 61 ± 13.6 0.002
Male, no. (%) 3 (12.5) 14 (73.7) 0.61
Female, no. (%) 2 (8.3) 5 (26.3)
IE type, no. (%)
Left-sided NVE 5 (100) 12 (63.2) 0.27
Left-sided PVE 0 5 (26.3) 0.54
Right-sided IE 0 2 (10.5) 1
Community-acquired 5 (100) 14 (73.7) 0.54
Nosocomial 0 5 (26.3) 0.54
Aetiology, no. (%)
Staphylococcus aureus 1 (20) 6 (31.6) 1
Coagulase-negative
staphylococci
0 5 (26.3) 0.544
Streptococcus viridans 3 (60) 1 (5.3) 0.02
Streptococcus bovis 0 1 (5.3) 1
Enterococcus faecalis 1 (20) 2 (10.5) 0.52
Candida spp. 0 2 (10.5) 1
Outcome
Renal failure, no. (%) 0 4 (21) 0.54
Hepatic failure, no. (%) 0 5 (26.3) 0.54
Total days of hospital
stay (median (IQR))
18 (12–53) 40 (34–74) 0.08
Days of stay after
surgery (median (IQR))
18 (11.5–43) 28 (24–44) 0.30
Mortality after
discharge, no. (%)
1 (20) 1 (5.3) 0.38
Relapse 0 0
Re-infection, no. (%) 1 (20) 0 0.21
IQR, interquartile range; NVE, native valve endocarditis; PVE, prosthetic valve
endocarditis; SD, standard deviation.
The bold values indicate the differences statistically signiﬁcant.
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Discussion
Our study suggests that a short course of antimicrobial ther-
apy may be adequate after surgical resection in patients with
IE, especially when caused by Streptococcus viridans or Strepto-
coccus bovis, even in patients at high risk of complications.
Current recommendations on the duration of postsurgical
treatment for IE are largely consensus-based. The result of
resected valve culture is a key element of the European
guidelines [7], which recommend completion of the sched-
uled antimicrobial course started before surgery if valve cul-
tures are negative, and a new full course of treatment if
valve cultures are positive, irrespective of the length of treat-
ment administered before surgery.
To date, only Morris et al. have investigated the safety of
a 2-week postsurgical treatment course in patients who have
undergone valve replacement for IE. They reported 54
patients (39 with natural valve IE and 15 with prosthetic
valve IE) who received £14 days of treatment after surgery;
all had negative valve cultures and 11 had perivalvular inva-
sion [8]. No increase in the relapse rate was observed in
these patients, although no other outcome data were analy-
sed. Our results show that mortality, relapse and re-infection
rates were similar in the SAT and LAT groups, whereas the
length of hospital stay was signiﬁcantly shorter in the SAT
group. Furthermore, we found a trend towards lower renal
and hepatic toxicity in patients treated for a maximum of
20 days after surgery. Factors independently associated with
SAT in our study were IE caused by Streptococcus viridans or
IE caused by Streptococcus bovis, whereas a positive result of
valve culture was associated with LAT.
Our group and others have already demonstrated that the
results of valve culture have to be interpreted with caution,
because of the frequently high rate of false-positive and false-
negative results [13,14,18]. In our series, 24 patients had
positive culture results at surgery—19 in the LAT group and
ﬁve in the SAT group—with no signiﬁcant differences in out-
come between them (Table 5).
Our study has some limitations. First, it is not a prospec-
tive comparative study and, despite our selection of high-risk
cases, the SAT and LAT groups are not similar with regard
to the presence of endocavitary devices, healthcare-related
cases, and the species causing IE. However, it does provide
the best evidence available to date on this condition, and we
hope that it will serve as a trigger for multicentre prospec-
tive trials comparing short and long courses of postsurgical
antimicrobial therapy. Second, because of the retrospective
design of the study, we were unable to investigate the con-
sequences of SAT and LAT with respect to other important
adverse effects of prolonged antibiotic therapy, such as oto-
toxicity, Clostridium difﬁcile-associated diarrhoea, and overall
cost of IE treatment. Third, the relatively small number of
patients and the evolution of surgical and medical practices
over time may limit our conclusions.
A short course of postsurgical antimicrobial therapy might
be safe, especially when IE is caused by Streptococcus viridans
or Streptococcus bovis, even in patients at high risk of compli-
cations. It reduces length of stay and antibiotic toxicity con-
siderably. Our results suggest that prospective trials
TABLE 6. Characteristics of the ﬁve patients with positive valve cultures who received short-course antimicrobial therapy
after surgery
Case Year
Sex/Age
(years) Predisposing
condition Type of IE Aetiology
Days of
ABT before
surgery Embolism
Perivalvular
extension
Surgical ﬁndings and
procedures Outcome
1 1996 Male/57 None Aortic NVE Streptococcus
viridans
0 No No Rupture of a leaﬂet.
Mechanical valve replacement
Cure
2 1999 Male/41 History of IV
drug use
Mitral NVE Enterococcus
faecalis
2 No Yes Extensive vegetation and
perforation of the
anteromedial leaﬂet.
Mechanical valve replacement
Cure
3 2003 Female/19 None (bicuspid
aortic valve)
Aortic NVE Streptococcus
viridans
0 No Yes Destruction of leaﬂets and
periaortic abscess. Drainage
and mechanical valve
replacement
Cure
4 2006 Male/28 Current IV
drug use
Mitral NVE MSSA 14 Skin lesion Yes Pericardiac inﬂammation,
extensive adherence and
vegetations on both leaﬂets.
Biological valve replacement
Re-infection
1 year later by
same species
but with
different
ﬁngerprint
5 2006 Female/35 None Mitral NVE Streptococcus
mitis
1 No No Vegetation on the
anteromedial leaﬂet. Valve
repair and annuloplasty
Cure
ABT, antibiotic therapy; IE, infective endocarditis; IV, intravenous; MSSA, methicillin-sensitive Staphylococcus aureus; NVE, native valve endocarditis.
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comparing short and long courses of antimicrobial therapy
after surgical resection of intracardiac tissue in patients with
IE are not only ethically acceptable but also necessary.
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